ITGA4 and acute myeloid leukemia: Notably, this study showed that the expression of METTL3 in AML patients was associated with adverse treatment outcomes and further confirmed that METTL3 regulated AML chemoresistance by mediating homing/engraftment and m6A methylation of ITGA4 mRNA, which might guide the clinical application of METTL3 inhibitors in the treatment of AML.